Background Infliximab (IFX) infusions require repeated hospitalizations. The median
duration of each hospitalization stay, including time for infusion and the cost for the health …

AIM To assess the impact of short infliximab (IFX) infusion on hospital resource utilization
and costs. METHODS All inflammatory bowel diseases (IBD) patients who received IFX 1 h …

BACKGROUND Infliximab and other intravenous biologic infusions are increasingly used for
chronic disorders like inflammatory bowel disease (IBD). Rapid infliximab and home-based …

Background and aims: Biological therapy with anti TNF agents requires parenteral
administration and in the case of infliximab this involves in hospital treatment. We aimed to …

Aim To estimate the impact of infliximab (IFX) on hospital resources for patients with Crohn's
disease. Methods Resource use data for at least 1 year before (B‐IFX) and after (A‐IFX) …

METHODS: Longitudinal patient data were obtained from the Optum Clinformatics Data
Mart. The analysis considered all patients with IBD who received infliximab from 2003 to …

AIM: To study the safety and effectiveness associated with accelerated infliximab infusion
protocols in patients with inflammatory bowel disease (IBD). METHODS: Original protocols …

Background Infliximab is a monoclonal antibody used in the treatment of inflammatory bowel
disease (IBD). The manufacturer-recommended administration is over 2 hours followed by 2 …

OBJECTIVES: Scheduled maintenance therapy with infliximab decreases the risk of infusion
reactions. Many centers have accelerated infusion times to 1 h in selected patients who …

Background: Anti‐tumor necrosis factor (TNF) medications have similar efficacy in Crohn's
disease (CD), but have not been compared in the real world. This study compared health …